#Drug #Gastroenterology

Mesalazine

evan April 8, 2024

Drug Class	Aminosalicylates
Mechanism	Release 5-aminosalicyclate acid in the bowel
Typical Dose	2.4-4.8g OD
Indications	Mild-moderate ulcerative colitis/Crohn's Maintenance of remission RA
Contra-indications	Salicylate hypersensitivity Renal impairment
Side-effects	GI disturbances Headache Arthralgia Leucopenia
Interactions	No severe
Elimination
Additional Notes	Renal impairment should be monitored for 3 months prior to starting treatment, and annually during treatment